scholarly journals Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice

2007 ◽  
Vol 18 ◽  
pp. vi124-vi127 ◽  
Author(s):  
V. Gebbia ◽  
E. Maiello ◽  
F. Giuliani ◽  
N. Borsellino ◽  
M. Caruso ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Pancreatic Carcinoma ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Multicenter Survey ◽  
Advanced Pancreatic Carcinoma ◽  
Line Chemotherapy

Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: Lessons from clinical practice

2011 ◽  
Vol 97 (3) ◽  
pp. 275-279 ◽  
Author(s):  
Mirco Pistelli ◽  
Mario Scartozzi ◽  
Alessandro Bittoni ◽  
Eva Galizia ◽  
Rossana Berardi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Practice ◽  
Metastatic Gastric Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey

Lung Cancer ◽  
2012 ◽  
Vol 75 (3) ◽  
pp. 360-367 ◽  
Author(s):  
P.A. Zucali ◽  
M. Simonelli ◽  
G. Michetti ◽  
M. Tiseo ◽  
G.L. Ceresoli ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Pleural Mesothelioma ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Multicenter Survey ◽  
Line Chemotherapy

A Case of Duodenal Neuroendocrine Carcinoma Treated with Amrubicin as Second-line Chemotherapy

2015 ◽  
Vol 24 (3) ◽  
pp. 379-382
Author(s):  
Tadahisa Inoue ◽  
Hitoshi Sano ◽  
Takashi Mizushima ◽  
Hirotada Nishie ◽  
Hiroyasu Iwasaki ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Distant Metastases ◽  
Salvage Chemotherapy ◽  
Second Line ◽  
Effective Treatment Option ◽  
Second Line Chemotherapy ◽  
Best Response ◽  
Long Term Effect ◽  
Line Chemotherapy

We present the case of a Japanese man in his 60s with duodenal neuroendocrine carcinoma with distant metastases. Chemotherapy with irinotecan plus cisplatin was initiated as a first-line regimen. However, disease progression was observed after only two cycles. Therefore, amrubicin was administered as a second-line chemotherapy. The patient showed a long-term effect of amrubicin therapy, and the best response was a partial response after seven cycles. For duodenal neuroendocrine carcinoma, amrubicin therapy can be considered an effective treatment option as salvage chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document